8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2020

2390 East Orangewood Avenue, Suite 500

Anaheim, California 92806

(Address of Principal Executive Office) (Zip Code)

(714) 462-4880

(Registrant’s telephone number, including area code)

_______________________________________

(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01 Other Events.

On January 30, 2020, BioCorRx Inc. (the “Company”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has confirmed the Company has been awarded a second year of funding to support the development of a 3-month implantable depot pellet of naltrexone for the treatment of Opioid Use Disorder. The Company refers to this treatment as BICX102. The amount awarded, $2,831,838, remains unchanged from the previously announced Notice of Award issued to the Company in January 2019.

On January 30, 2020, the Company issued a press release announcing the events described in this Item 8.01. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits*.*

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

bicx_ex991.htm EXHIBIT 99.1

BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA

Grant for the Development of BICX102, a Sustained Release Naltrexone

Implant for the Treatment of Opioid Use Disorder

ANAHEIM, CA, January 30, 2020 – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, has been awarded an additional $2.8 million. This is the second tranche from the total grant of approximately $5.7 million announced last year. The grant was awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number UG3DA047925. The grant is for the development of BICX102, the Company’s 3-month, sustained release naltrexone implant for the treatment of opioid use disorder. The Company is seeking FDA approval for BICX102.

This notice of award is the result of the Company’s application under RFA DA-19-002, “Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)”. The total amount for the UG3 phase is $5,674,268. In the original application, the Company also requested over $3.6 million for the subsequent UH3 phase. The UH3 award is anticipated at a later date upon completion of milestones stated in the application, which would enable transition from the UG3 to UH3 phase and based on availability of funds.

Brady Granier, CEO, President, and Director of BioCorRx, Inc., stated, “We are pleased to receive the notice of award for the second tranche of this non-dilutive NIDA grant funding, which we believe further validates the progress we have achieved to date with BICX102. We continue to move forward through the development and regulatory process for BICX102. This grant is expected to substantially cover our financial costs towards FDA approval. Our goal this year is to get IND approval so that we can start conducting human studies.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance use; please visit www.beataddiction.com for more information on the BioCorRx Recovery Program. The UnCraveRx™ Weight Loss Program is also a medication assisted program; please visit www.uncraverx.com for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.

investors@BioCorRx.com

714-462-4880

Investor Relations:

Crescendo Communications, LLC

(212) 671-1020 x304

bicx@crescendo-ir.com